drugset / Trial / NCT04921878

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

NCT04921878

Phase 1 Completed 29 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of mitoxantrone hydrochloride liposome injection in patients with advanced solid tumors.

Timeline

Start
2021-07-30
Primary completion
2023-04-03
Completion
2023-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 24 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 30 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 36 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 40 mg/m2 Intravenous

Indications